tiprankstipranks

Paul Blake. Insider Profile

4 Followers
Paul Blake., Chief Development Officer at Oxford BioMedica, holds 2.62M shares in Oxford BioMedica (Ticker: OXBDF), holds 70.35K shares in Aeterna Zentaris (Ticker: AEZS). Most recently, Paul Blake. Bought ― shares of Oxford BioMedica on Mar 16, 2015 for an estimated value of 10.00K.
tipranks
Paul Blake.

Paul Blake.
Oxford BioMedica (OXBDF)
Chief Development Officer

Ranked #1,997 out of 98,743 Corporate Insiders

Profitable Transactions

80%
4 out of 5 Profitable Transactions

Average Return

+115.90%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark

Insider Holdings

$11M
94.72%
5.28%
A breakdown of Paul Blake.'s holdings

Insider Roles

Oxford BioMedica
(OXBDF)
Chief Development Officer
Aeterna Zentaris
(AEZS)
Former
Roles that Paul Blake. holds in companies

Most Profitable Insider Trade

Stock:
Oxford BioMedica
(OXBDF)
Rating:Informative Buy
Date:Jul 01, 2014 - Jul 01, 2015
Return:+267.50%
The most profitable trade made by Paul Blake.

Paul Blake.'s Trading History

Company Name
Last Transaction Date
Insider Position
Last Transaction
Last Transaction Amount
Holding Value
Oxford BioMedica
Mar 16, 2015
Chief Development Officer
Informative Buy
10.00K
$10.13M
Aeterna Zentaris
Sep 28, 2011
Former
Informative Buy
8.10K
$564.91K
List of latest transactions for each holding click on a transaction to see Paul Blake.'s performance on stock

Paul Blake. insider profile FAQ

What is the percentage of profitable transactions made by Paul Blake.?
The percentage of profitable transactions made by Paul Blake. is 80%.
    What is the average return per transaction made by Paul Blake.?
    The average return per transaction made by Paul Blake. is 115.90%.
      What stocks does Paul Blake. hold?
      Paul Blake. holds: OXBDF, AEZS stocks.
        What was Paul Blake.’s latest transaction?
        Paul Blake. latest transaction was an Informative Buy of $10.00K.
          What was Paul Blake.'s most profitable transaction?
          Paul Blake.’s most profitable transaction was an Informative Buy of OXBDF stock on July 1, 2014. The return on the trade was 267.50%.
            What is Paul Blake.'s role in Oxford BioMedica?
            Paul Blake.'s role in Oxford BioMedica is Chief Development Officer.
              How can I follow the stock ratings of top corporate insiders?
              Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.